How to Vet an Online Compounded GLP-1 Prescription

On June 16, 2026, FDA posted a batch of warning letters involving telehealth marketing of compounded GLP-1 drugs. For patients, the takeaway is not that every compounded prescription is automatically unsafe. It is that a polished website is not enough to prove that a product is equivalent to an FDA-reviewed drug. ([fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters))

The short answer to the trust question is: sometimes, but not on marketing claims alone. FDA says compounded GLP-1 drugs are not FDA-approved, and the agency recommends using compounded versions only when a patient’s medical needs cannot be met by an FDA-approved drug or when the approved drug is not commercially available. FDA also advises patients to get a prescription from their doctor and fill it at a state-licensed pharmacy. ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))

Why this matters now

Online compounded GLP-1 offers have become more visible as people look for lower prices, easier access, or alternatives to brand-name drugs. NIDDK notes that some, but not all, insurance plans cover medications that treat overweight and obesity, which helps explain why patients may look beyond FDA-approved products. But lower cost or easier access does not erase the need to verify what you are actually being sold. ([niddk.nih.gov](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity))

It is also important to be precise about what a warning letter means. FDA warning letters are formal regulatory notices describing what the agency believes are violations, and FDA notes on its warning-letter page that later interactions can change the regulatory status of the issues discussed. ([fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters))

FDA-approved GLP-1 drugs are not the same as compounded versions

NIDDK lists semaglutide, tirzepatide, and liraglutide among FDA-approved prescription medicines used in weight management in specific circumstances. Compounded versions are different: FDA says compounded drugs do not go through FDA’s premarket review for safety, effectiveness, or quality. That distinction matters because a compounded product may sound similar to a brand-name GLP-1, while still lacking the same review, labeling, manufacturing oversight, and evidence base. ([niddk.nih.gov](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity))

What FDA said was misleading in the June letters

In FDA’s June 8, 2026 warning letter to Momentum Health 360, the agency cited marketing that linked compounded semaglutide and tirzepatide to brand-name GLP-1 products and said those claims made the compounded products appear FDA-approved or otherwise evaluated for safety and effectiveness when they were not. FDA also objected to language describing a compounding facility as FDA-licensed, saying pharmacies and outsourcing facilities are not FDA-approved or FDA-licensed entities. ([fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/momentum-health-360-dba-momentum-health-728286-06082026))

For patients, the practical lesson is simple: wording such as same active ingredient, found in a well-known brand, or made in an FDA-licensed facility can blur important differences. FDA’s concern is that these phrases can make a compounded product sound interchangeable with an approved drug when it is not. ([fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/momentum-health-360-dba-momentum-health-728286-06082026))

Red flags to spot before you pay

FDA tells consumers to watch for several warning signs when buying GLP-1 drugs online. These include:

Claims that a compounded drug is the same as an FDA-approved drug. ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))
Deep discounts or prices that seem too good to be true. ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))
No screening or prescription by a licensed doctor before the medication is provided. ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))
No licensed doctor available to answer questions after the medication arrives. ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))
Packaging that is broken, damaged, different from what was pictured, or missing instructions for use. ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))
Label spelling errors, incorrect pharmacy addresses, or a pharmacy name that may be fraudulent. ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))

AMA physician guidance adds a broader caution: patients should look past online hype and marketing promises and start with a conversation with a doctor, because some injectable peptides promoted online are not well regulated and may carry real health risks. ([ama-assn.org](https://www.ama-assn.org/public-health/prevention-wellness/what-doctors-want-patients-know-about-injectable-peptides))

Safety concerns go beyond marketing

Shipping and refrigeration

FDA says injectable GLP-1 drugs require refrigeration according to their package inserts. The agency has received complaints about certain compounded GLP-1 products arriving warm or with inadequate ice packs, and it recommends that patients not use an injectable GLP-1 drug that arrives warm or without sufficient refrigeration because that can affect the drug’s quality. ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))

Dosing errors

FDA says it has received multiple reports of adverse events, some requiring hospitalization, tied to dosing errors with compounded injectable semaglutide. According to the agency, some patients measured and self-administered the wrong dose, while in other cases health professionals miscalculated doses. FDA also says some reports involved doses or dose increases beyond FDA-approved labeling. ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))

Salt forms and questionable ingredients

FDA warns that some semaglutide products sold by compounders may use salt forms such as semaglutide sodium or semaglutide acetate. The agency says those are different active ingredients from the semaglutide used in approved drugs, does not have information showing they have the same chemical and pharmacologic properties, and is not aware of a lawful basis for their use in compounding. ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))

Fraudulent labels and underreported harms

FDA says it is aware of fraudulent compounded semaglutide and tirzepatide products marketed in the United States with false label information, including cases involving nonexistent or falsely named compounders. FDA also says adverse events are likely underreported because many state-licensed pharmacies are not required by federal law to submit adverse-event reports to the agency. As of May 31, 2026, FDA said it had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA also notes that those reports do not always prove the drug itself directly caused the event. ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))

Questions to ask before you use an online compounded GLP-1

Before you pay or take the first dose, ask clear questions and expect clear answers:

Is this an FDA-approved product or a compounded drug? ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))
Which state-licensed pharmacy or outsourcing facility is filling it? ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))
What exactly is the active ingredient, strength, and concentration? ([fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/momentum-health-360-dba-momentum-health-728286-06082026))
Does it contain added ingredients, and if so, why? ([fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/momentum-health-360-dba-momentum-health-728286-06082026))
How should it be shipped, stored, and handled when it arrives? ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))
What syringe, pen, or measuring device should be used, and what is the exact dose schedule? ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))
Who should you call if the package arrives warm, damaged, mislabeled, or without instructions? ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))
Are there FDA-approved alternatives, and does your insurance cover any of them? ([niddk.nih.gov](https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity))

If the answers are vague, overly sales-focused, or inconsistent, that is a reason to slow down and verify more before using the medication. ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))

When to call a clinician, pharmacist, or seek urgent help

Contact your prescriber or pharmacist promptly if the drug arrives warm, damaged, missing instructions, or looking different from what you expected, or if you are unsure how to measure the dose. FDA specifically advises patients to contact the compounder or telehealth platform if they have questions about instructions for use or label information. ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))

Seek urgent or emergency care for severe symptoms such as trouble breathing, facial swelling, fainting, severe or worsening abdominal pain, repeated vomiting or diarrhea with signs of dehydration, or another serious reaction after using the product. If you are already taking a GLP-1 medicine, do not start, stop, or change your treatment plan on your own based on online marketing alone; get advice from the clinician or pharmacist involved in your care. ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss))

The bottom line

FDA’s June 2026 warning letters do not mean every compounded GLP-1 prescription is automatically unsafe. They do mean patients should be skeptical of online marketing that makes a compounded drug sound interchangeable with an FDA-approved one. The safest next step is to verify the prescriber, verify the pharmacy, confirm exactly what product is being dispensed, and make sure you have usable storage and dosing instructions before you take it. ([fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters))

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.